TickerTalks
Browse all tickers →
TickerTalks›$GILD
GIGILD

Gilead Sciences, Inc.

$GILD·$161B·Drug Manufacturers - General·Healthcare
$136.30+3.5%YTD+11.3%1Y+24.1%
Mentions · last 7 days
2026-07-09: 211 posts2026-07-10: 240 posts2026-07-11: 68 posts2026-07-12: 131 posts2026-07-13: 599 posts2026-07-14: 161 posts2026-07-15: 202 posts1,621+3%
Price updated 4m ago·X counts updated 2d ago
GIGILD
$GILDGilead Sciences, Inc.
$136.30+3.49%1.6k posts+3%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $GILD, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-07-16

The move is getting stronger, with heavier trading behind it.

HIV + oncology compounder at 17x with a fresh technical breakout — earnings hit August 6.

Gilead Sciences is the HIV franchise leader (Biktarvy) with a growing oncology + cell-therapy portfolio. The stock is up 21% t12m with a fresh technical breakout that the community reads as a real sentiment shift into the August 6 print.

  • The core business is executing cleanly: Q1 2026 revenue grew 4.4% YoY to $6.96B, gross margin held at 79%, and operating margin was 37% — HIV as a mature-but-growing franchise plus the Trodelvy/Yescarta oncology contribution is exactly the mid-cap biotech setup value investors want.
  • The valuation is defensible: 17x TTM P/E and 5.4x sales for a business earning 38% operating margins with 6.4% FCF yield puts GILD at a discount to broader biotech peers — the discount reflects historical HIV-patent-cliff concerns that the pipeline (lenacapavir, etc.) has partly resolved.
  • The insider action is quiet and constructive: only 1 insider event in the quarter with no scale distribution, and community positioning describes GILD as breaking over resistance with a shift of sentiment — the setup is a technical + fundamental confluence into the August 6 print.

The August 6 Q2 earnings are the near-term arbiter — Biktarvy volume trajectory, Trodelvy/Yescarta revenue growth, and any specific lenacapavir launch commentary extend the setup toward the sell-side high targets. A HIV volume miss or Trodelvy market-share softening stalls the tape sub-$130.

Agrees with X sentimentX is bullish, cites GILD +5-6% from community entries, framing 'breaking over resistance - shift of sentiment,' and groups GILD with REGN as big-pharma buys. Mechanics validate: 17x P/E, 79% gross margin, 6.4% FCF yield, Q1 revenue +4.4% YoY. The technical + fundamental confluence is real — the August 6 print has to affirm HIV volume and Trodelvy trajectory.

What to watch: The August 6 Q2 earnings. Watch Biktarvy volume trajectory, Trodelvy/Yescarta revenue growth, and lenacapavir launch commentary. HIV volume miss or Trodelvy share softening stalls the tape sub-$130; steady numbers extend toward sell-side high targets.

On the calendar: 2026-08-06 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment6 posts analyzed · as of 2026-07-15

Gilead chatter is bullish. GILD is up ~5-6% from where community bought a few days ago. Bulls see GILD 'breaking over resistance - shift of sentiment.' Community groups GILD with REGN as big pharma buys. H.C. Wainwright commentary on ALGS and Pevy positioning discusses GILD as one of the peers. Community broadly long.

Read the AI verdict + X sentiment for $GILD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Sells Biktarvy for HIV, Veklury for COVID, and Trodelvy for oncology; large-cap specialty pharma with antiviral and cancer drug focus.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $GILD.

Drug Manufacturers - General · Healthcare

No material change from last week — oral semaglutide versus injectable Zepbound, with Amgen, Pfizer, and AZ all presenting obesity pipeline data.

What this means for $GILD

Partial — Sells Biktarvy for HIV, Veklury for COVID, and Trodelvy for oncology; large-cap specialty pharma with antiviral and cancer drug focus; this segment overlaps with the oral GLP-1 and obesity pipeline expansion and competition but is not the dominant revenue driver.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+17.8%YTD
+47.7%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
17.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
20.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
38.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
42.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
79.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.9Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$2.03$1.91+6.3%
Q4 2025Feb 10, 2026$1.86$1.81+2.8%
Q3 2025Oct 30, 2025$2.47$2.13+16.0%
Q2 2025Aug 7, 2025$2.01$1.96+2.6%
Next earningsThu, Aug 6·consensus EPS $-7.29

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$7.0B+4.4%79.2%37.2%$1.63$2.4B
Q4 FY25$7.9B+4.7%79.5%37.7%$1.76$3.1B
Q3 FY25$7.8B+3.0%79.8%42.8%$2.46$4.0B
Q2 FY25$7.1B+1.8%78.8%34.9%$1.57$720.0M

Forward consensus

5-year forecast · up to 20 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$30.5B$30.2B – $30.7B-$0.78-$1.02 – -$0.6318
FY27$32.4B$31.3B – $33.9B$9.69$9.07 – $11.1618
FY28$34.2B$34.2B – $34.3B$10.56$7.90 – $12.1620
FY29$36.8B$35.9B – $38.1B$12.05$11.66 – $12.6211
FY30$38.7B$37.7B – $40.1B$13.10$12.68 – $13.7311

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.58%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+4.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+4.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.2B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.345-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 15Andrew D DickinsonCFO3.0K sh$390KSellJul 15Johanna MercierChief Comm & Corp Aff Officer3.0K sh$390KSellJul 1O'day Daniel PatrickCEO15.0K sh$1.9MSellJun 15Johanna MercierChief Comm & Corp Aff Officer3.0K sh$372KSellJun 15Andrew D DickinsonCFO3.0K sh$376KSellJun 1O'day Daniel PatrickCEO15.0K sh$2.0MSellMay 15Andrew D DickinsonCFO3.0K sh$397KSellMay 15Johanna MercierChief Comm & Corp Aff Officer28.0K sh$3.7MSellApr 28O'day Daniel PatrickCEO10.0K sh$1.3MSellApr 15Johanna MercierChief Comm & Corp Aff Officer3.0K sh$423K
1–10 of 14
+ 32 other (12 awards · 10 exempts · 10 inkinds) in window

See when $GILD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentMay 27SC 13D/A
AI summary

With filed Amendment No. 4 to Schedule 13D disclosing updated beneficial ownership in GILD (GILD). The filing covers approximately 4,977,089 shares of GILD. The position is held for potential M&A activity. Schedule 13D amendments are required when a 5%-or-greater holder's ownership, intent, or plans change materially, providing transparency into concentrated positions that could influence corporate governance or trigger M&A activity.

8-KMaterial agreementMay 208-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation · Item 8.01: Other event
AI summary

Gilead Sciences, Inc. (GILD) filed an 8-K on May 14, 2026 disclosing a material definitive agreement (Item 1.01), creation of a direct financial obligation (Item 2.03), and an other-event disclosure (Item 8.01). Gilead is a Foster City, California-based biopharmaceutical company focused on HIV, hepatitis, and oncology listed on Nasdaq. Filed concurrently with Gilead's $3B debt offering (424B5), Items 1.01 and 2.03 likely reflect the indenture for that debt issuance; this is a significant capital market event for the large-cap biopharma company.

424B5Prospectus supplement (offering)May 18424B5
AI summary

Gilead Sciences, Inc. (GILD) priced a $3 billion four-tranche senior notes offering on May 18, 2026, comprising: $500M 4.250% Notes due May 20, 2028; $1B 4.400% Notes due May 20, 2029; $1B 4.600% Notes due May 20, 2031; and $500M 4.900% Notes due May 20, 2034. Interest is payable semi-annually on May 20 and November 20 each year starting November 2026. This is a large investment-grade debt capital markets transaction for Gilead; proceeds are likely for general corporate purposes, which may include funding pipeline acquisitions or licensing deals given Gilead's active M&A history.

424B5Prospectus supplement (offering)May 14424B5
AI summary

Gilead Sciences, Inc. (GILD) filed a preliminary 424B5 on May 14, 2026 for a multi-tranche senior notes offering with all pricing terms blank (amounts, rates, and maturities pending final terms). This preliminary filing precedes the final 424B5 pricing on May 18, 2026 which established the $3B four-tranche deal. The blank terms confirm this is the preliminary prospectus supplement and the actual deal economics were determined the following day.

8-KShareholder voteMay 48-K — Item 5.07: Shareholder vote
AI summary

Gilead Sciences Inc. (GILD) filed an 8-K reporting results of its annual shareholders' meeting under Item 5.07. Shareholders voted on standard governance matters including election of directors, ratification of the independent auditor, and advisory votes on executive compensation. All management-supported proposals passed as expected at the major pharmaceutical company. Detailed vote tallies by proposal are included in the filing.

SC 13D/AActivist amendmentApr 28SC 13D/A
AI summary

Gilead Sciences Inc. (GILD) received an amended Schedule 13D/A (Amendment No. 1) in connection with its ownership of Arcellx Inc. shares, where Gilead holds more than 5% and files as an active rather than passive holder. This amendment updates Gilead's beneficial ownership position in the oncology biotech following prior transactions. As a strategic investor with collaboration arrangements, Gilead filed under the more active 13D rather than passive 13G form. The filing discloses current share counts and updated purpose of the investment.

8-KPress release / Reg FDApr 288-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Gilead Sciences Inc. (GILD) filed an 8-K under Items 7.01 and 8.01 disclosing investor materials under Regulation FD and reporting other material events. The pharmaceutical company made conference presentation materials, pipeline updates, or investor communications publicly available to ensure equal access. The Item 8.01 disclosure may cover clinical data readouts, partnership announcements, or regulatory updates. Exhibits contain the substantive disclosed materials.

SC 13DActivist position (5%+)Feb 23SC 13D
+ 23 other (5 13Gs · 3 SC TO-T/As · 2 13Fs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Knowzacks.com·1d agoIs the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity?247wallst.com·2d agoCongo begins trial of Gilead's experimental antiviral for Ebola Bundibugyoreuters.com·3d agoMany Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.fool.com·5d agoGilead Sciences (GILD) Stock Dips While Market Gains: Key Factszacks.com·7d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LLY$NVO$JNJ$PFE$MRK$ABBV$OGN$AMGN
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport